Inhibition of serum-induced M-phase progression by a tyrosine kinase inhibitor, erbstatin.
A tyrosine kinase inhibitor, erbstatin, increased the number of M-phase cells in exponentially growing NRK, NIH3T3, and RSV-NRK cells. In synchronized NRK cells prepared by serum starvation or hydroxyurea treatment, erbstatin also increased the number of M-phase cells in the presence of serum when added before M-phase. Erbstatin did not inhibit serum-induced DNA synthesis at all. The accumulated M-phase cells later divided even in the presence of erbstatin, indicating that the effect of erbstatin is reversible. An inactive analogue, 5'-O-methylerbstatin, did not increase the number of mitotic figures. Flow cytometric analysis indicated that erbstatin reversibly accumulated 4n DNA containing cells when added to G1/S-synchronized NRK cells. Increased cellular H1 kinase activity at M-phase is decreased after mitosis, and this decrease was inhibited by erbstatin. Thus tyrosine kinase is suggested to be involved in the progression of the M-phase.